SARS-CoV-2 viral protection drug efficacy evaluation clinical study

JRCT ID: jRCTs031230405

Registered date:17/10/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: COVID-19
• Date of first enrollment: 17/10/2023
• Target sample size: 20
• Study type: Interventional
• Intervention(s): Application of drug

Outcome(s)

• Primary Outcome: Safety Assessment
• Secondary Outcome: Improvement of the symptom and change (%) in COVID-19 PCR values (before treatment) after 4 days of treatment

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1.SARS-CoV-2 positive patient(less than severity type II)
2.Written informed consent
3.Over age 20 at the time of informed consent

Exclude criteria

1. Those who have been more than 10 days since the onset of COVID-19, or those with a negative SARS-CoV-2 PCR.
2. Pregnant or possibly pregnant or lactating patients
3. Who are unable to perform the PCR test by themselves.
4. Who has used any research drug within 1 week of the start of the study
5. Any other person whom the principal investigator or sub-investigator determines to be inappropriate to conduct this study.

Related Information

• Primary Sponsor: Takagi Gen
• Secondary Sponsor: Nishino Takeshi,Nezu Life Science Co. Ltd.